|
Video: What is a Stock Split?
|
|
Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Co.'s primary development candidate, tucatinib, is an orally bioavailable, potent tyrosine kinase inhibitor that is selective for HER2, a growth factor receptor that is over-expressed in about 20.0% of breast cancers. Co. is developing tucatinib for the treatment of HER2-positive metastatic breast cancer. Co.'s earlier stage product candidate, CASC-578, is a checkpoint kinase 1 cell cycle inhibitor that is an orally available, small molecule kinase inhibitor and additionally Co. has an antibody against an immuno-oncology target known as TIGIT. According to our CASC split history records, CASC has had 1 split. | |
|
CASC (CASC) has 1 split in our CASC split history database. The split for CASC took place on November 29, 2016. This was a 1 for 6 reverse split, meaning for each 6 shares of CASC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as CASC conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CASC split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CASC shares, starting with a $10,000 purchase of CASC, presented on a split-history-adjusted basis factoring in the complete CASC split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
03/12/2018 |
|
Start price/share: |
$16.80 |
|
End price/share: |
$10.02 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-40.36% |
|
Average Annual Total Return: |
-12.50% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,963.48 |
|
Years: |
3.87 |
|
|
|
Date |
Ratio |
11/29/2016 | 1 for 6 |
|
|